TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy

Abstract

Objective: Thyrotoxicosis is established risk factor for osteoporosis due to increased bone turnover. Glucocorticoids often administered for Graves' orbitopathy (GO) have additional negative effect on bone mineral density (BMD). Our aim was to examine the influence of thyroid hormones, TSH, TSH-receptor antibodies (TRAb) and glucocorticoid treatment on bone in women with Graves' thyrotoxicosis and Graves' orbitopathy (GO). Subjects and methods: Forty seven women with Graves' disease, mean age 55.6 ± 12.8 (23 women with thyrotoxicosis and 24 hyperthyroid with concomitant GO and glucocorticoid therapy) and 40 age-matched healthy female controls were enrolled in the study. We analyzed clinical features, TSH, FT4, FT3, TRAb, TPO antibodies. BMD of lumbar spine and hip was measured by DEXA and 10-year fracture risk was calculated with FRAX tool. Results: The study showed significantly lower spine and femoral BMD (g/cm 2 ) in patients with and without GO compared to controls, as well as significantly higher fracture risk. Comparison between hyperthyroid patients without and with orbitopathy found out significantly lower spine BMD in the first group (p = 0.0049). Negative correlations between FT3 and femoral neck BMD (p = 0.0001), between FT4 and BMD (p = 0.049) and positive between TSH and BMD (p = 0.0001), TRAb and BMD (p = 0.026) were observed. Fracture risk for major fractures and TRAb were negatively associated (p = 0.05). We found negative correlation of BMD to duration of thyrotoxicosis and cumulative steroid dose. Conclusions: Our results confirm the negative effect of hyperthyroid status on BMD. TRAb, often in high titers in patients with GO, may have protective role for the bone, but further research is needed. Arch Endocrinol Metab. 2018;62(2):221-6

Effects of Growth-Related Genes on Body Measurement Traits in Wenshang Barred Chickens

“…IGFs regulate bone length, radial bone growth, and cortical and trabecular bone properties via their effects on osteoblast, osteocyte, and osteoclast functions (Yakar et al, 2018;Halmos and Suba, 2019). Direct effects of TSH on bone traits have been reported, and TSH is a single necessary molecular switch that negatively regulates skeletal remodeling (Siderova et al, 2018). In addition to the action of pituitary TSH on osteoblasts and osteoclasts, the bone marrow microenvironment acts as an endocrine circuit that produces a novel TSH-β subunit variant, which is positively regulated by T3.…”

Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation

“…In contrast, TSH exerts a positive effect on this parameter. TSH receptor antibodies are often present at a high titer in patients with Graves' ophthalmopathy and may exert a protective effect on bone [26].…”

Impact of Graves’ Disease and Antithyroid Drug Therapy on Bone Mineral Density – Pathophysiological Mechanisms and Clinical Relevance

“…whether overt or subclinical hyperthyroidism or euthyroidism are present, as well as the type of the existing antibodies (blocking or stimulating). In overt hyperthyroidism, antiTSH-R could have a protective role, while in subclinical hyperthyroidism or an euthyroid state they could accelerate bone loss ( 41 ). Some researchers did not find a direct causal association or the underlying mechanism.…”

“…In hyperthyroidism, the bone remodeling cycles are more frequent, and the cycle is shortened so it lasts 3-4 months, which is shorter by about 50% ( 63 ). The formation phase is more reduced than resorption, consequently leading to bone loss of 10% per cycle ( 41 ). Thyroid hormones have direct effects on osteoblasts and chondrocytes.…”